Tetrahydrocannabinol/cannabidiol (THC/CBD), also known as CanChew or MedChew, is a combination of the cannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD) which is or was under development for the treatment of dementia, pain, Parkinson's disease, postherpetic neuralgia, psychotic disorders, restless legs syndrome (RLS), and irritable bowel syndrome (IBS).[1][2][3] It is taken bucally as a chewing gum.[1][2] The drug is or was under development by Axim Biotech.[1][2] As of May 2023, no recent development has been reported for all indications.[1]
 Tetrahydrocannabinol (THC) | |
 Cannabidiol (CBD) | |
| Combination of | |
|---|---|
| Tetrahydrocannabinol | Cannabinoid |
| Cannabidiol | Cannabinoid |
| Clinical data | |
| Other names | Cannabidiol/tetrahydrocannabinol; THC/CBD; CBD/THC; CanChew; MedChew |
| Routes of administration | Buccal (chewing gum)[1] |
See also
editReferences
edit- 1 2 3 4 5 "Cannabidiol/tetrahydrocannabinol". AdisInsight. 28 May 2023. Retrieved 2 June 2026.
- 1 2 3 Pressman P, Hayes AW, Hamam AM, Vaillancourt K, Miladinovic T, Rana A, et al. (2025). "Chewing Gum as a Delivery System for Cannabidiol: A Commentary". Medical Cannabis and Cannabinoids. 8 (1): 158–165. doi:10.1159/000547917. PMC 12503730. PMID 41064746.
- ↑ Martínez V, Iriondo De-Hond A, Borrelli F, Capasso R, Del Castillo MD, Abalo R (April 2020). "Cannabidiol and Other Non-Psychoactive Cannabinoids for Prevention and Treatment of Gastrointestinal Disorders: Useful Nutraceuticals?". International Journal of Molecular Sciences. 21 (9): 3067. doi:10.3390/ijms21093067. PMC 7246936. PMID 32357565.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by adding missing information. |